New figures from the UK Health Security Agency (UKHSA) show that syphilis diagnoses in England continued to rise in 2024 compared to 2023.

Across the past decade, rates of syphilis have roughly doubled, including infectious cases. Genital herpes cases fell substantially in 2020 but have rebounded most of the way since, while the number of chlamydia cases has fallen slightly. Gonorrhea cases have doubles while genital warts cases have halved.

Among people in England:

  • infectious syphilis diagnoses increased 1.7% from 9,375 in 2023 to 9,535 in 2024; considering all syphilis diagnoses, including late stage or complications such as ocular and otosyphilis, diagnoses increased 4.6% from 12,456 in 2023 to 13,030 in 2024
  • gonorrhoea diagnoses decreased 15.9% from 85,370 in 2023 to 71,802 in 2024
  • chlamydia diagnoses decreased by 13.0% from 194,143 diagnoses in 2023 to 168,889 diagnoses in 2024
  • first episode genital warts diagnoses decreased 4.3% from 26,193 in 2023 to 25,056 diagnoses in 2024
  • new STI diagnoses decreased 8.8% from 399,947 in 2023 to 364,750 in 2024
  • the diagnosis rates of STIs remain greatest in young people aged 15 to 24 years; gay, bisexual and other men who have sex with men (GBMSM); and some minority ethnic groups

Among women aged 15 to 24 years who are recommended to be screened through the National Chlamydia Screening Programme (NCSP):

  • there was a 10.7% decrease in the number of chlamydia tests carried out, from 673,102 in 2023 to 601,295 in 2024
  • there was a decrease of 18.0% in the number of chlamydia diagnoses, from 64,802 in 2023 to 53,166 in 2024; test positivity also decreased (from 9.6% in 2023 to 8.8% in 2024)

Syphilis is mostly growing among heterosexual men and women, but is also growing among women who have sex with women, while rates among men who have sex with men are growing more slowly.

In November 2023 the Joint Committee on Vaccination and Immunisation advised a targeted vaccination programme for gonorrhoea in to be rolled out by sexual health services; eligible people will be offered the vaccine from August 2025.